Biomarkers Predict Total Joint Replacements in Osteoarthritis Patients
|
By LabMedica International staff writers Posted on 22 May 2019 |
|
Image: Knee osteoarthritis, also known as degenerative joint disease, is typically the result of wear and tear and progressive loss of articular cartilage (Photo courtesy of Bruce Blaus).
Osteoarthritis (OA) in major joints ultimately leads to joint failure for which the only curative treatment is total joint replacement. This procedure is associated with risk of complications and approximately 20% continue to experience pain.
Biomarkers may act as tools in investigating the association between biochemical and pathological processes and risk of joint failure. C-telopeptide of cross-linked collagen type I (CTX-I) and C-telopeptide of cross-linked collagen type II (CTX-II) are both considered biomarkers that may reflect disease progression in OA.
Scientists from the Krembil Research Institute (Toronto, ON, Canada) performed a post-hoc analysis, looking at data from two clinical trials that involved the use of oral supplements. They included subjects with available baseline serum CTX-I and urine CTX-II for biomarker analyses. There were a total of 27 total joint replacements (TJR), 19 knee replacements, and eight hip replacements. Investigators compared the risk of TJR of the knee or hip in patients with high versus low biomarker values using statistical analysis that controlled for age, sex, and body mass index.
The team showed that high baseline urine CTX-II was significantly associated with an elevated (3.08 times) risk of undergoing a TJR of the knee or hip during the period of study. For risk of knee replacement alone, patients with elevated CTX-I had an 8.94 times elevated risk. Elevated baseline serum CTX-I was associated with a 3.4 times higher risk of undergoing knee or hip replacement. However, this biomarker did not attain statistical significance for risk of knee arthroplasty alone.
Jonathan J. Bjerre-Bastos, MD, from Nordic Bioscience (Copenhagen, Denmark), and the lead author of the study, said, “Osteoarthritis is the most common indication for total joint replacement. Total joint replacement is an expensive procedure associated with complications and a portion of patients continue to have pain after surgery.” The study was published in the April 2019 issue of the journal Osteoarthritis and Cartilage.
Related Links:
Krembil Research Institute
Nordic Bioscience
 Reagent.jpg)
Biomarkers may act as tools in investigating the association between biochemical and pathological processes and risk of joint failure. C-telopeptide of cross-linked collagen type I (CTX-I) and C-telopeptide of cross-linked collagen type II (CTX-II) are both considered biomarkers that may reflect disease progression in OA.
Scientists from the Krembil Research Institute (Toronto, ON, Canada) performed a post-hoc analysis, looking at data from two clinical trials that involved the use of oral supplements. They included subjects with available baseline serum CTX-I and urine CTX-II for biomarker analyses. There were a total of 27 total joint replacements (TJR), 19 knee replacements, and eight hip replacements. Investigators compared the risk of TJR of the knee or hip in patients with high versus low biomarker values using statistical analysis that controlled for age, sex, and body mass index.
The team showed that high baseline urine CTX-II was significantly associated with an elevated (3.08 times) risk of undergoing a TJR of the knee or hip during the period of study. For risk of knee replacement alone, patients with elevated CTX-I had an 8.94 times elevated risk. Elevated baseline serum CTX-I was associated with a 3.4 times higher risk of undergoing knee or hip replacement. However, this biomarker did not attain statistical significance for risk of knee arthroplasty alone.
Jonathan J. Bjerre-Bastos, MD, from Nordic Bioscience (Copenhagen, Denmark), and the lead author of the study, said, “Osteoarthritis is the most common indication for total joint replacement. Total joint replacement is an expensive procedure associated with complications and a portion of patients continue to have pain after surgery.” The study was published in the April 2019 issue of the journal Osteoarthritis and Cartilage.
Related Links:
Krembil Research Institute
Nordic Bioscience
Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
New
Gold Member
Liquid Ready-To-Use Lp(a) Reagent
Lipoprotein (a) Reagent
Latest Clinical Chem. News
- 3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models
- POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection
- Highly Reliable Cell-Based Assay Enables Accurate Diagnosis of Endocrine Diseases
- New Blood Testing Method Detects Potent Opioids in Under Three Minutes
- Wireless Hepatitis B Test Kit Completes Screening and Data Collection in One Step
- Pain-Free, Low-Cost, Sensitive, Radiation-Free Device Detects Breast Cancer in Urine
- Spit Test Detects Breast Cancer in Five Seconds
- Electrochemical Sensors with Next-Generation Coating Advances Precision Diagnostics at POC
- First-Of-Its-Kind Handheld Device Accurately Detects Fentanyl in Urine within Seconds
- New Fluorescent Sensor Array Lights up Alzheimer’s-Related Proteins for Earlier Detection
- Automated Mass Spectrometry-Based Clinical Analyzer Could Transform Lab Testing
- Highly Sensitive pH Sensor to Aid Detection of Cancers and Vector-Borne Viruses
- Non-Invasive Sensor Monitors Changes in Saliva Compositions to Rapidly Diagnose Diabetes
- Breakthrough Immunoassays to Aid in Risk Assessment of Preeclampsia
- Urine Test for Monitoring Changes in Kidney Health Markers Can Predict New-Onset Heart Failure
- AACC Releases Comprehensive Diabetes Testing Guidelines
Channels
Molecular Diagnostics
view channel
Novel Biomarkers to Improve Diagnosis of Renal Cell Carcinoma Subtypes
Renal cell carcinomas (RCCs) are notably diverse, encompassing over 20 distinct subtypes and generally categorized into clear cell and non-clear cell types; around 20% of all RCCs fall into the non-clear... Read more
RNA-Powered Molecular Test to Help Combat Early-Age Onset Colorectal Cancer
Colorectal cancer (CRC) ranks as the second most lethal cancer in the United States. Nevertheless, many Americans eligible for screening do not undergo testing due to limited access or reluctance towards... Read more
Hematology
view channel
Next Generation Instrument Screens for Hemoglobin Disorders in Newborns
Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more
First 4-in-1 Nucleic Acid Test for Arbovirus Screening to Reduce Risk of Transfusion-Transmitted Infections
Arboviruses represent an emerging global health threat, exacerbated by climate change and increased international travel that is facilitating their spread across new regions. Chikungunya, dengue, West... Read more
POC Finger-Prick Blood Test Determines Risk of Neutropenic Sepsis in Patients Undergoing Chemotherapy
Neutropenia, a decrease in neutrophils (a type of white blood cell crucial for fighting infections), is a frequent side effect of certain cancer treatments. This condition elevates the risk of infections,... Read more
First Affordable and Rapid Test for Beta Thalassemia Demonstrates 99% Diagnostic Accuracy
Hemoglobin disorders rank as some of the most prevalent monogenic diseases globally. Among various hemoglobin disorders, beta thalassemia, a hereditary blood disorder, affects about 1.5% of the world's... Read moreImmunology
view channel
Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies
Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more
AI Tool Precisely Matches Cancer Drugs to Patients Using Information from Each Tumor Cell
Current strategies for matching cancer patients with specific treatments often depend on bulk sequencing of tumor DNA and RNA, which provides an average profile from all cells within a tumor sample.... Read more
Genetic Testing Combined With Personalized Drug Screening On Tumor Samples to Revolutionize Cancer Treatment
Cancer treatment typically adheres to a standard of care—established, statistically validated regimens that are effective for the majority of patients. However, the disease’s inherent variability means... Read more
Microbiology
view channel
Integrated Solution Ushers New Era of Automated Tuberculosis Testing
Tuberculosis (TB) is responsible for 1.3 million deaths every year, positioning it as one of the top killers globally due to a single infectious agent. In 2022, around 10.6 million people were diagnosed... Read more
Automated Sepsis Test System Enables Rapid Diagnosis for Patients with Severe Bloodstream Infections
Sepsis affects up to 50 million people globally each year, with bacteraemia, formerly known as blood poisoning, being a major cause. In the United States alone, approximately two million individuals are... Read more
Enhanced Rapid Syndromic Molecular Diagnostic Solution Detects Broad Range of Infectious Diseases
GenMark Diagnostics (Carlsbad, CA, USA), a member of the Roche Group (Basel, Switzerland), has rebranded its ePlex® system as the cobas eplex system. This rebranding under the globally renowned cobas name... Read more
Clinical Decision Support Software a Game-Changer in Antimicrobial Resistance Battle
Antimicrobial resistance (AMR) is a serious global public health concern that claims millions of lives every year. It primarily results from the inappropriate and excessive use of antibiotics, which reduces... Read morePathology
view channel
Hyperspectral Dark-Field Microscopy Enables Rapid and Accurate Identification of Cancerous Tissues
Breast cancer remains a major cause of cancer-related mortality among women. Breast-conserving surgery (BCS), also known as lumpectomy, is the removal of the cancerous lump and a small margin of surrounding tissue.... Read more
AI Advancements Enable Leap into 3D Pathology
Human tissue is complex, intricate, and naturally three-dimensional. However, the thin two-dimensional tissue slices commonly used by pathologists to diagnose diseases provide only a limited view of the... Read more
New Blood Test Device Modeled on Leeches to Help Diagnose Malaria
Many individuals have a fear of needles, making the experience of having blood drawn from their arm particularly distressing. An alternative method involves taking blood from the fingertip or earlobe,... Read more
Robotic Blood Drawing Device to Revolutionize Sample Collection for Diagnostic Testing
Blood drawing is performed billions of times each year worldwide, playing a critical role in diagnostic procedures. Despite its importance, clinical laboratories are dealing with significant staff shortages,... Read moreTechnology
view channel
New Diagnostic System Achieves PCR Testing Accuracy
While PCR tests are the gold standard of accuracy for virology testing, they come with limitations such as complexity, the need for skilled lab operators, and longer result times. They also require complex... Read more
DNA Biosensor Enables Early Diagnosis of Cervical Cancer
Molybdenum disulfide (MoS2), recognized for its potential to form two-dimensional nanosheets like graphene, is a material that's increasingly catching the eye of the scientific community.... Read more
Self-Heating Microfluidic Devices Can Detect Diseases in Tiny Blood or Fluid Samples
Microfluidics, which are miniature devices that control the flow of liquids and facilitate chemical reactions, play a key role in disease detection from small samples of blood or other fluids.... Read more
Breakthrough in Diagnostic Technology Could Make On-The-Spot Testing Widely Accessible
Home testing gained significant importance during the COVID-19 pandemic, yet the availability of rapid tests is limited, and most of them can only drive one liquid across the strip, leading to continued... Read moreIndustry
view channel
Danaher and Johns Hopkins University Collaborate to Improve Neurological Diagnosis
Unlike severe traumatic brain injury (TBI), mild TBI often does not show clear correlations with abnormalities detected through head computed tomography (CT) scans. Consequently, there is a pressing need... Read more
Beckman Coulter and MeMed Expand Host Immune Response Diagnostics Partnership
Beckman Coulter Diagnostics (Brea, CA, USA) and MeMed BV (Haifa, Israel) have expanded their host immune response diagnostics partnership. Beckman Coulter is now an authorized distributor of the MeMed... Read more_1.jpg "Image: Thermo Fisher will distribute Bio-Techne products across Europe (Photo courtesy of 123RF)")
